🇺🇸 FDA
Pipeline program

Ivonescimab

24-6289

Phase 2 mab active

Quick answer

Ivonescimab for Thymus Carcinoma is a Phase 2 program (mab) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Summit Therapeutics
Indication
Thymus Carcinoma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials